Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T. Siddiqi
Safety of Lisocabtagene Maraleucel Given With Durvalumab in Patients With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma: First Results From the Platform Study
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Combination of TGR-1202, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients With Advanced DLBCL and Follicular Lymphoma.
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
MDS as a Cause for Prolonged Hematologic Toxicity After Treatment With Cd19 Targeted Car-T Cell Therapy in Patients With Relapsed Refractory Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Transcend CLL 004: Minimal Residual Disease After Lisocabtagene Maraleucel in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Preliminary Efficacy in Patients With Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Product Characteristics Associated With in Vivo Expansion of Anti-Cd19 Car T Cells in Patients Treated With Axicabtagene Ciloleucel (Axi-Cel)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
